BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Wu JY, Kang K, Yi J, Yang B. Pembrolizumab-induced Stevens-Johnson syndrome in advanced squamous cell carcinoma of the lung: A case report and review of literature. World J Clin Cases 2022; 10(18): 6110-6118 [PMID: 35949835 DOI: 10.12998/wjcc.v10.i18.6110]
URL: https://www.wjgnet.com/2307-8960/full/v10/i18/6110.htm
Number Citing Articles
1
Yen T.H. Pham, Mai T. Vu, Anh Q. Nguyen, Phat N. Trinh, Mai H. Tran, Hieu C. Chu, Nguyet T.M. Nguyen, Chi H.V. Vu, Dinh V. Nguyen. Pembrolizumab-induced Stevens-Johnson syndrome/Toxic Epidermal Necrolysis in a Vietnamese patient with nonsmall-cell lung cancerAsia Pacific Allergy 2023;  doi: 10.5415/apallergy.0000000000000131
2
Pembrolizumab/prednisoneReactions Weekly 2022; 1917(1): 481 doi: 10.1007/s40278-022-20352-y
3
Takashi K. Satoh, Matthias Munoz Neulinger, Pia‐Charlotte Stadler, Rui Aoki, Lars E. French. Immune checkpoint inhibitor‐induced epidermal necrolysis: A narrative review evaluating demographics, clinical features, and culprit medicationsThe Journal of Dermatology 2024; 51(1): 3 doi: 10.1111/1346-8138.17039
4
Jia Zhou, Chuan-Peng Wang, Jun Li, Han-Lin Zhang, Chun-Xia He. Stevens-Johnson syndrome and toxic epidermal necrolysis associated with immune checkpoint inhibitors: a systematic reviewFrontiers in Immunology 2024; 15 doi: 10.3389/fimmu.2024.1414136